News Article | May 25, 2017
— RnRMarketResearch.com adds “Peritoneal Cancer - Pipeline Review, H1 2017” to its store providing an overview of the Peritoneal Cancer therapeutic pipeline with comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. Complete report on H1 2017 pipeline review of Peritoneal Cancer spread across 759 pages is available at http://www.rnrmarketresearch.com/peritoneal-cancer-pipeline-review-h1-2017-market-report.html . Peritoneal Cancer Pipeline report also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 3-V Biosciences Inc, AbbVie Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Altor BioScience Corp, Amgen Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celsion Corp, CerRx Inc, Clovis Oncology Inc, Critical Outcome Technologies Inc, Dr. Reddy's Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Company, EpiThany Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genor BioPharma Co Ltd, Glycotope GmbH, Gradalis Inc, Hemispherx Biopharma Inc, ImmunoGen Inc, Immunovaccine Inc, Incyte Corp, Innate Pharma SA, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Lidds AB, Mabion SA, MabVax Therapeutics Holdings Inc, Mateon Therapeutics Inc, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, MolMed SpA, Mycenax Biotech Inc, NewLink Genetics Corp, Novartis AG, Novogen Ltd, Oasmia Pharmaceutical AB, OBI Pharma Inc, Oncobiologics Inc, Oncolix Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, Polaris Pharmaceuticals Inc, PsiOxus Therapeutics Ltd, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Sanofi Pasteur SA, Sotio AS, Syndax Pharmaceuticals Inc, TapImmune Inc, Tyrogenex Inc, Vascular Biogenics Ltd, VentiRx Pharmaceuticals Inc, Verastem Inc Get Discount on This Report At http://www.rnrmarketresearch.com/contacts/discount?rname=1001938 (This report is available at upto 25% Discount till 02 June 2017.) Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy. Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 60, 36, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 1 molecule, respectively. Direct Purchase of This Research Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1001938 . Scope of this report: The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer and reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Peritoneal Cancer. About Us: RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.rnrmarketresearch.com/peritoneal-cancer-pipeline-review-h1-2017-market-report.html
News Article | May 23, 2017
Today, on May 23, 2017, an annual shareholders' meeting was held in Saniona AB (publ). A summary of the resolutions adopted follows below. All resolutions were adopted with the necessary majority of votes. Resolution on adoption of accounts and distribution of the company's profit The annual shareholders' meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual shareholders' meeting also resolved to distribute the company's result in accordance with the proposal from the board in the annual report meaning that no dividends are paid for the financial year 2016 and that available funds are carried forward to a new account. Discharge from liability for the board of directors and the CEO The annual shareholders' meeting resolved to discharge the board of directors and the CEO from liability for the financial year 2016. Election of board members and auditor as well as remuneration for the board members and auditor The annual shareholders' meeting resolved, in accordance with the proposal from the Nomination Committee, to re-elect Claus Braestrup, Leif Andersson, Jørgen Drejer and Carl Johan Sundberg as ordinary board members. Claus Braestrup was re-elected as Chairman of the board. Remuneration to the board shall be paid with SEK 110,000 to Carl Johan Sundberg, whereas no remuneration shall be paid to other board members. Furthermore, the annual shareholders' meeting resolved, in accordance with the proposal from the Nomination Committee, to re-elect Deloitte AB as the accounting firm and that the remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Deloitte AB has notified that the certified accountant Elna Lembrér Åström will continue to be the auditor in charge. Resolution on instruction and charter for the Nomination Committee The annual shareholders' meeting resolved, in accordance with the proposal from the Nomination Committee, that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the board. Furthermore, an instruction and charter for the Nomination Committee was adopted. The annual shareholders' meeting resolved, in accordance with the proposal from the board, to adopt a Remuneration Policy for determination of salary and other conditions for the CEO and other senior executives. Resolution on authorization for the board of directors regarding new issues The annual shareholders' meeting resolved, in accordance with the proposal from the board, to authorize the board to, at one or several occasions, during the time up until the next annual shareholders' meeting, with or without deviation from the shareholders' preferential rights, resolve to issue shares, convertibles and/or warrants. A new issue should be able to be made with or without provisions regarding contribution in kind, set-off or other conditions. In case the authorization is used for a new issue with deviation from the shareholders' preferential rights, the number of shares, that may be issued or alternatively be issued through conversion of convertibles or by exercise of warrants, shall not exceed 30 per cent of the total number of existing shares in the company at the time of the annual shareholders' meeting and the subscription price shall be on market terms (subject to customary new issue discount, as applicable). The purpose of the authorization is to be able to source working capital, to be able to execute and finance acquisitions of companies as well as to enable new issues to industrial partners within the framework of partnerships and alliances. Resolution on (a) employee option program; and (b) directed issue of warrants and approval of transfer of warrants The annual shareholders' meeting resolved, in accordance with the proposal from the board, to adopt an employee option program for certain employees and key consultants who are active within the Saniona Group in Denmark. The program implies that a maximum of 38,750 employee options shall be offered to certain employees and key consultants who are active within the Saniona Group in Denmark. The holders shall be entitled to exercise allotted and vested employee options during 30 days from the day following after the announcement of the company's quarterly reports, or for full year, the year-end report, the first time after the announcement of the quarterly report for the first quarter of 2021 and the last time after the announcement of the quarterly report for the third quarter of 2022. If the company does not render any quarterly report or year-end report after the end of any calendar quarter, the allotted and vested employee options may instead be exercised during the last month of the following calendar quarter, the first time in June 2021 and the last time in December 2022. Each employee option entitles the holder a right to acquire one new share in the company against cash consideration at a subscription price amounting to 100 per cent of the average closing price of the company's share on Nasdaq First North Premier during ten trading days after the 2017 annual shareholders' meeting. The employee options shall be allotted without consideration, and the employee options shall not constitute securities and shall not be able to be transferred or pledged. In order to enable the company's delivery of shares under the employee option program, the annual shareholders' meeting resolved to issue a maximum of 38,750 warrants to a subsidiary within the Saniona Group in Denmark. The warrants may thereafter be transferred to the participants in the employee option program without consideration in connection with the exercise of employee options. The purpose of the employee option program is to secure a long term commitment for the employees and key consultants within the Saniona Group through a compensation system which is linked to the Company's future value growth. In case all warrants under the employee option program are exercised, a total of 38,750 shares will be issued, which corresponds to a dilution of approximately 0.19 per cent of the Company's share capital and votes. For more information, please contact The information was submitted for publication, through the agency of the contact person set out above, at 17:40 CET on 23 May 2017. Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Luc Therapeutics Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 5,000 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.
News Article | May 24, 2017
— Ulcerative Colitis - Pipeline Review, H1 2017 market research report adds on ReportsnReports.com store. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse Ulcerative Colitis Pipeline report has 85 Company Profiles, 121 Tables and 11 Figures, Spread across 409 Pages Report Available at http://www.reportsnreports.com/reports/992899-ulcerative-colitis-pipeline-review-h1-2017.html . Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. Main key players of Ulcerative Colitis are 4D Pharma PLC, AbbVie Inc, AbGenomics International Inc, Abivax SA, Adello Biologics LLC, Advinus Therapeutics Ltd, Aerpio Therapeutics Inc, Akebia Therapeutics Inc, Allergan Plc, Am-Pharma BV, Amgen Inc, Aptevo Therapeutics Inc, Arena Pharmaceuticals Inc, Atlantic Bio Sci LLC, Atlantic Healthcare Plc, Blueberry Therapeutics Ltd, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, ChemoCentryx Inc, ChironWells GmbH, Circle33 LLC, Coherus BioSciences Inc, Cosmo Pharmaceuticals NV, Dr. August Wolff GmbH & Co KG Arzneimittle, Dr. Falk Pharma GmbH, EA Pharma Co Ltd, Eli Lilly and Company, Enceladus Pharmaceuticals BV, Enterome Bioscience SA, Ferring International Center SA, Galapagos NV, Genentech Inc, Genor BioPharma Co Ltd more.. Discount Available at http://www.reportsnreports.com/contacts/discount.aspx?name=992899 (This report is available at upto 25% Discount till June 02nd 2017.) Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Ulcerative Colitis – Pipeline market report provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Order a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=992899 Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal). • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) Table of Contents: Table of Contents Introduction Ulcerative Colitis - Overview Ulcerative Colitis - Therapeutics Development Ulcerative Colitis - Therapeutics Assessment Ulcerative Colitis - Companies Involved in Therapeutics Development Ulcerative Colitis - Drug Profiles Ulcerative Colitis - Dormant Projects Ulcerative Colitis - Discontinued Products Ulcerative Colitis - Product Development Milestones Appendix 3 About Us: ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details at email@example.com and we would be happy to help you find the business intelligence that you need. ReportsnReports.com offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more. For more information, please visit http://www.reportsnreports.com/reports/992899-ulcerative-colitis-pipeline-review-h1-2017.html